JPRN-jRCT2080221401已完成3 期
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Male and female ,adult outpatients aged>=18 years
- •To Meet DSM-IV-TR diagnostic criteria for MDD assessed by the Mini-International Neuropsychiatric Interview (MINI)
- •Partial response to a course of SSRI treatment and the SSRI treatment must be at a stable
- •Patients must have a score >=16 on the GRID 17-Item Hamilton Depression Rating Scale (GRID-HAMD17) total score
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG)MedDRA version: 17.0Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMyasthenia GravisEUCTR2011-002068-26-DEGlaxoSmithKline Research & Development Limited42
进行中（未招募）
不适用
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG)Subjects with Generalized Myasthenia Gravis (MG)MedDRA version: 14.0Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002068-26-ITGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.42
进行中（未招募）
不适用
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) TreatmentMajor depressive disorder (MDD)MedDRA version: 15.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-021215-16-HUEli Lilly and Company1,178
已完成
3 期
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentMajor Depressive DisoderJPRN-jRCT2080221400Eli Lilly Japan K.K.
招募中
1 期
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of InflammatioEarly Alzheimer’s Disease with Biomarkers of InflammationMedDRA version: 20.0Level: PTClassification code: 10012293Term: Dementia of the Alzheimer's type uncomplicated Class: 100000004852CTIS2023-505396-71-00Inmune Bio Inc.189